Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress
November 05, 2020 16:01 ET
|
Fate Therapeutics, Inc.
First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma FT596 Phase 1 Study Expanded to Include Chronic Lymphocytic Leukemia First...
Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting
November 05, 2020 08:00 ET
|
Fate Therapeutics, Inc.
Four Oral Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation Company to Host Investor Event on Friday, December 4 SAN DIEGO, Nov. 05, 2020 ...
Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting
October 15, 2020 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress
May 11, 2020 16:01 ET
|
Fate Therapeutics, Inc.
Worldwide Collaboration Formed with Janssen for Novel iPSC-derived CAR NK and CAR T-Cell Product Candidates First Patient Treated with FT596, the First-ever Cellular Immunotherapy Engineered with...
Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting
December 10, 2019 09:51 ET
|
Fate Therapeutics, Inc.
FT819 Exhibits Enhanced Tumor Clearance In Vivo Compared to Primary CAR T Cells in Preclinical Leukemia Model Master Engineered iPSC Line for FT819 Fully Characterized for Complete Elimination of TCR...
Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy
December 08, 2019 10:39 ET
|
Fate Therapeutics, Inc.
FT596 as a Monotherapy Demonstrates Comparable Anti-tumor Activity to CAR19 T Cells In Vivo in Humanized Mouse Model of Lymphoma Combination of FT596 with Rituximab Shows Durable Tumor Clearance In...
Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs
December 07, 2019 08:40 ET
|
Fate Therapeutics, Inc.
No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing Cycle No Dose-limiting Toxicities or...
Fate Therapeutics Announces Issuance of Foundational U.S. Patent Covering iPSC-derived CAR T Cells
August 14, 2019 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development
April 18, 2019 08:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, April 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting
April 01, 2019 08:01 ET
|
Fate Therapeutics, Inc.
High-Throughput Selection of a Single Gene-Edited iPSC Enables Mass Production of Uniformly Engineered CAR T Cells FT819 Off-the-Shelf CAR19 T-cell Product Candidate Demonstrates Complete...